Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
As of close of business last night, Acadia Pharmaceuticals Inc’s stock clocked out at $17.52, up 0.06% from its previous closing price of $17.51. In other words, the price has increased by $0.06 from its previous closing price. On the day, 1.51 million shares were traded. ACAD stock price reached its highest trading level at $17.68 during the session, while it also had its lowest trading level at $17.21.
Ratios:
To gain a deeper understanding of ACAD’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.16 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.38. For the most recent quarter (mrq), Quick Ratio is recorded 2.11 and its Current Ratio is at 2.29. In the meantime, Its Debt-to-Equity ratio is 0.09 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Guggenheim on January 03, 2025, Downgraded its rating to Neutral and sets its target price to $20 from $23 previously.
Morgan Stanley Downgraded its Overweight to Equal-Weight on August 07, 2024, whereas the target price for the stock was revised from $28 to $20.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 19 ’24 when Teehan Brendan sold 10,329 shares for $16.81 per share. The transaction valued at 173,630 led to the insider holds 62,105 shares of the business.
Kihara James sold 4,073 shares of ACAD for $68,467 on Nov 19 ’24. The PRINCIPAL ACCOUNTING OFFICER now owns 19,863 shares after completing the transaction at $16.81 per share. On Nov 19 ’24, another insider, Schneyer Mark C., who serves as the EVP, CHIEF FINANCIAL OFFICER of the company, sold 10,259 shares for $16.81 each. As a result, the insider received 172,454 and left with 53,302 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ACAD now has a Market Capitalization of 2915187968 and an Enterprise Value of 2399225856. As of this moment, Acadia’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.68, and their Forward P/E ratio for the next fiscal year is 23.14. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.14 while its Price-to-Book (P/B) ratio in mrq is 5.05. Its current Enterprise Value per Revenue stands at 2.582 whereas that against EBITDA is 19.265.
Stock Price History:
The Beta on a monthly basis for ACAD is 0.37, which has changed by -0.3580066 over the last 52 weeks, in comparison to a change of 0.22677135 over the same period for the S&P500. Over the past 52 weeks, ACAD has reached a high of $29.29, while it has fallen to a 52-week low of $14.15. The 50-Day Moving Average of the stock is 2.50%, while the 200-Day Moving Average is calculated to be 6.97%.
Shares Statistics:
It appears that ACAD traded 2.35M shares on average per day over the past three months and 5791280 shares per day over the past ten days. A total of 166.35M shares are outstanding, with a floating share count of 164.30M. Insiders hold about 1.26% of the company’s shares, while institutions hold 94.08% stake in the company. Shares short for ACAD as of 1735603200 were 10718622 with a Short Ratio of 4.57, compared to 1732838400 on 9906399. Therefore, it implies a Short% of Shares Outstanding of 10718622 and a Short% of Float of 8.7.
